Copper Blood Test: When to Order It and What the Results Mean

What Is a Copper Blood Test?

A serum copper test quantifies the total copper concentration in plasma or serum. Copper is an essential trace mineral that acts as a cofactor for at least a dozen metalloenzymes, including cytochrome c oxidase, superoxide dismutase, and ceruloplasmin itself. The NIH Office of Dietary Supplements notes that the adult body contains roughly 50 to 120 milligrams of copper, with the highest concentrations in the liver, brain, heart, and kidneys.

About 65 to 90 percent of circulating copper is bound to ceruloplasmin, a glycoprotein made in the liver. The remainder travels loosely bound to albumin or as free ionic copper. That distinction matters clinically: Wilson disease produces a paradox where total serum copper may appear low or normal because ceruloplasmin-bound copper drops sharply, yet "free" or non-ceruloplasmin-bound copper actually rises and deposits in tissues.

How the Test Is Performed

Blood is drawn into a metal-free (trace-element) tube, typically a royal-blue-top EDTA or serum separator tube certified for trace-metal analysis. Standard tubes contaminated with copper can falsely raise the result. The specimen goes to an inductively coupled plasma mass spectrometry (ICP-MS) analyzer or an atomic absorption spectrometer. Neither method requires the patient to fast.

Why Ceruloplasmin Accompanies Serum Copper

Ordering serum copper without ceruloplasmin is like ordering a CBC without a differential: you get a number without context. A 2019 review in the journal Hepatology confirmed that the combination of serum ceruloplasmin <20 mg/dL plus Kayser-Fleischer rings carries a diagnostic sensitivity of about 56 percent for Wilson disease when used alone, rising to greater than 95 percent when a 24-hour urine copper exceeding 100 micrograms per day is added to the panel.

When Should a Clinician Order a Copper Test?

Copper testing is not a routine screening panel like a basic metabolic panel or a lipid profile. Clinicians order it when the clinical picture specifically points toward copper excess, copper insufficiency, or a disease process in which copper metabolism is a known mechanism.

Suspected Wilson Disease

Wilson disease is the clearest indication. It is an autosomal recessive disorder of the ATP7B gene that impairs hepatic copper excretion. The AASLD 2023 practice guidance on Wilson disease recommends measuring serum copper, ceruloplasmin, and 24-hour urine copper in any patient under 40 years old with unexplained hepatitis, cirrhosis, or acute liver failure. The guidance assigns this a Grade I, Level B recommendation.

The classic Wilson disease laboratory pattern includes:

• Serum ceruloplasmin <20 mg/dL (normal 20 to 35 mg/dL)
• 24-hour urine copper >100 mcg/day (normal <50 mcg/day)
• Liver copper on biopsy >250 mcg per gram dry weight
• Serum copper that may be low-normal despite tissue overload

Neuropsychiatric symptoms, tremor, dysarthria, and Kayser-Fleischer rings on slit-lamp exam strengthen the case for testing.

Copper Deficiency Workup

Copper deficiency is underdiagnosed. It produces a clinical syndrome that resembles subacute combined degeneration of the spinal cord: sensory ataxia, spastic gait, and peripheral neuropathy. Hematologically, it causes anemia and leukopenia that can mimic myelodysplastic syndrome.

Common precipitants include:

• Gastric bypass or other bariatric procedures
• Prolonged parenteral nutrition without adequate trace-element supplementation
• Chronic zinc supplementation above 50 mg per day, which upregulates metallothionein in enterocytes and sequesters copper
• Celiac disease or other malabsorptive conditions

A 2006 case series published in the New England Journal of Medicine described 55 patients with copper deficiency myelopathy, the majority of whom had prior gastric surgery or excess zinc exposure. Order serum copper, ceruloplasmin, zinc, and a full CBC with differential when this picture appears.

Monitoring Zinc Supplementation

High-dose zinc supplementation, particularly zinc doses above 50 mg/day used for macular degeneration (following the AREDS2 protocol), age-related immune support, or misguided self-directed supplementation, can suppress copper absorption over months. The NIH Office of Dietary Supplements zinc fact sheet explicitly flags this interaction and recommends co-supplementation with 2 mg copper per day for anyone taking 25 mg zinc or more daily.

A baseline copper and ceruloplasmin before starting high-dose zinc, then a recheck at 3 to 6 months, is a reasonable clinical protocol.

Inflammatory and Malignant States

Copper behaves as a positive acute-phase reactant. Infection, autoimmune flares, pregnancy, and certain malignancies (particularly Hodgkin lymphoma and lung cancer) raise serum copper above 140 mcg/dL by increasing hepatic ceruloplasmin synthesis. A serum copper elevated in this context does not indicate Wilson disease or dietary copper excess. The clinical history and companion inflammatory markers (C-reactive protein, erythrocyte sedimentation rate) clarify the picture.

Occupational or Environmental Copper Exposure

Workers in copper mining, smelting, or plumbing who have sustained dermal or inhalational copper exposure may need periodic monitoring. The CDC's NIOSH Pocket Guide to Chemical Hazards lists the permissible exposure limit for copper fume at 0.1 mg/m3 as an 8-hour time-weighted average.

Normal Copper Range: What the Numbers Mean

Reference intervals vary slightly by laboratory, sex, and age. Most U.S. Reference labs report the following adult ranges:

| Population | Serum Copper (mcg/dL) | Serum Copper (micromol/L) | |---|---|---| | Adult men | 70 to 140 | 11 to 22 | | Adult women (non-pregnant) | 80 to 155 | 12.6 to 24.4 | | Pregnant women (third trimester) | 120 to 300 | 18.8 to 47.1 | | Children (1 to 12 years) | 80 to 160 | 12.6 to 25.1 | | Neonates | 20 to 70 | 3.1 to 11 |

Neonatal copper is physiologically low because placental transfer of copper is a late-pregnancy event. Premature infants are especially vulnerable to copper deficiency.

Pregnancy raises serum copper dramatically because estrogen increases hepatic ceruloplasmin synthesis. A serum copper of 200 mcg/dL in the third trimester is normal and should not trigger a Wilson disease workup without other supporting findings.

What Does a High Copper Level Mean?

Physiological Elevation

The most common cause of a mildly elevated serum copper in an outpatient is pregnancy or oral contraceptive use. Estrogen-containing medications raise ceruloplasmin by the same mechanism as pregnancy. No treatment is needed.

Inflammatory Elevation

Acute infection, rheumatoid arthritis flares, and systemic lupus erythematosus can push serum copper to 150 to 200 mcg/dL. A study in Clinical Chemistry (PMID 6690263) showed that ceruloplasmin rises within 24 to 48 hours of an acute inflammatory stimulus alongside fibrinogen and C-reactive protein, all as part of the hepatic acute-phase response.

Wilson Disease: The Counterintuitive Pattern

In Wilson disease, total serum copper may be deceptively normal or even low because ceruloplasmin is suppressed and the lab reports "total" copper, most of which is normally ceruloplasmin-bound. However, non-ceruloplasmin-bound ("free") copper, calculated as total serum copper minus (ceruloplasmin in mg/dL × 3), rises above 25 mcg/dL in active Wilson disease.

The AASLD 2023 guidance defines a free copper above 25 mcg/dL as one of the diagnostic criteria when other tests are borderline.

Copper Toxicosis from Supplements or Diet

Dietary copper toxicity from food alone is rare given normal gastrointestinal regulatory mechanisms. Supplement overdose or contaminated water from corroded copper pipes presents acutely with nausea, vomiting, and abdominal pain, and can produce serum copper well above 200 mcg/dL with transaminase elevation. FDA adverse event data and the NIH copper fact sheet cite a tolerable upper intake level (UL) of 10 mg per day for adults.

How to Lower Copper When It Is Truly Elevated

For Wilson disease, two FDA-approved chelating agents exist: penicillamine and trientine (trientine dihydrochloride, brand name Cuprior, approved by FDA in 2022). The FDA approval record for trientine dihydrochloride confirms its indication for Wilson disease in patients intolerant of penicillamine. Zinc acetate (Galzin) is also FDA-approved as maintenance therapy: it blocks intestinal copper absorption by inducing metallothionein.

For inflammatory copper elevation, treating the underlying condition normalizes levels without direct copper intervention.

For supplement-induced elevation, stopping the offending supplement is sufficient.

What Does a Low Copper Level Mean?

Recognizing Copper Deficiency

Serum copper below 70 mcg/dL in an adult, particularly when accompanied by low ceruloplasmin (<20 mg/dL), anemia, leukopenia, or neurological symptoms, warrants a deficiency workup. A low zinc level does not explain low copper; the two often move in opposite directions when zinc excess is the cause.

Common Causes of Low Copper

• Excess zinc: The most common iatrogenic cause. Metallothionein induction in the gut preferentially binds copper over zinc, blocking copper transport into the portal circulation.
• Malabsorption: Celiac disease, Crohn disease involving the proximal small bowel, and post-bariatric anatomy all reduce the absorptive surface area where copper uptake occurs.
• Menkes disease: A rare X-linked disorder of ATP7A, the copper-export pump expressed in intestinal cells. Affected infants have serum copper below 30 mcg/dL and present with kinky hair, seizures, and failure to thrive in the first months of life. Described in detail at NCBI GeneReviews.
• Total parenteral nutrition (TPN) without trace elements: Standard TPN formulations historically omitted or underdosed trace elements. Current ASPEN guidelines recommend 0.3 to 0.5 mg copper per day in adult TPN solutions.

How to Raise Copper When It Is Low

Oral copper supplementation at 2 mg per day of elemental copper (as copper gluconate, copper sulfate, or copper glycinate) corrects dietary or zinc-induced deficiency in most adults within 4 to 8 weeks. Severe neurological copper deficiency, particularly post-bariatric myelopathy, may require 4 to 8 mg per day orally or, rarely, intravenous copper histidinate in refractory cases.

A case series in the Archives of Neurology (PMID 16682538) documented partial neurological recovery in copper-deficient myelopathy patients after 3 to 6 months of supplementation, though improvement was incomplete in those with advanced cord changes. Earlier recognition and treatment produces better outcomes.

Stopping high-dose zinc is as important as starting copper. Without removing the competitive antagonist, supplemental copper may fail to raise serum levels adequately.

The Zinc-to-Copper Ratio: A Functional Marker Worth Knowing

The serum zinc-to-copper ratio (Zn:Cu ratio) has attracted interest as a functional marker of redox balance and inflammatory status. A ratio between 1.0 and 2.0 (in the same units, typically mcg/dL) is often cited as optimal in the functional medicine and integrative literature, though population-based normative data from large prospective cohorts remain limited.

A practical clinical framework for interpreting the zinc-to-copper ratio:

• Ratio <1.0: Relative copper excess or zinc insufficiency. Consider copper-lowering interventions only if clinical symptoms and Wilson disease have been excluded.
• Ratio 1.0 to 2.0: Generally balanced. No intervention indicated based on ratio alone.
• Ratio >2.0: Relative copper deficiency or zinc excess. Review zinc supplement doses, bariatric history, and malabsorption risk. Check CBC for anemia and leukopenia.

A 2021 analysis in the Journal of Trace Elements in Medicine and Biology (PMID 33217622) examined Zn:Cu ratios in 989 adults and found that ratios above 2.0 correlated with lower serum ceruloplasmin (r = -0.41, P<0.001), consistent with functional copper insufficiency even when absolute serum copper remained within the laboratory reference range.

Clinicians using this ratio should order both tests from the same blood draw using the same trace-element collection tubes to avoid pre-analytical variability.

Interpreting Copper in Specific Clinical Populations

Patients on GLP-1 Receptor Agonists or Significant Weight Loss

Rapid weight loss from GLP-1 receptor agonist therapy (e.g., semaglutide 2.4 mg weekly in STEP-1, which produced 14.9 percent mean weight loss at 68 weeks in N=1,961 participants vs. 2.4 percent for placebo NEJM 2021, PMID 34170647) can unmask subclinical malabsorption. Patients who have previously undergone bariatric surgery and then add a GLP-1 agent face compounded malabsorption risk. A baseline copper and ceruloplasmin panel before starting semaglutide or tirzepatide is reasonable in anyone with a prior bariatric procedure.

Patients on Testosterone Replacement Therapy (TRT)

Testosterone does not directly regulate copper metabolism, but men on TRT who self-add high-dose zinc supplements (sometimes marketed alongside testosterone for "natural testosterone support") accumulate copper deficiency risk. Any TRT patient reporting fatigue, gait changes, or unexplained anemia while taking supplemental zinc above 25 mg/day warrants a copper and ceruloplasmin check.

Postmenopausal Women on Hormone Therapy

Estrogen-containing hormone therapy raises ceruloplasmin and total serum copper, typically by 20 to 30 percent above baseline. A 1992 study in Metabolism (PMID 1625534) showed that oral estradiol raised serum ceruloplasmin by 28 percent at 3 months in 42 postmenopausal women, whereas transdermal estradiol produced no significant change. Transdermal routes of administration avoid first-pass hepatic ceruloplasmin induction, meaning the route of estrogen delivery affects how you interpret copper results.

Ordering the Right Panel: A Practical Summary

A single serum copper result rarely stands alone. The table below shows the recommended companion tests by clinical indication.

| Clinical Scenario | Serum Copper | Ceruloplasmin | 24-hr Urine Copper | Serum Zinc | CBC | LFTs | |---|---|---|---|---|---|---| | Suspected Wilson disease | Yes | Yes | Yes | No | Yes | Yes | | Copper deficiency workup | Yes | Yes | No | Yes | Yes | No | | High-dose zinc monitoring | Yes | Yes | No | Yes | No | No | | Inflammatory / malignancy copper rise | Yes | Yes | No | No | No | Yes | | Menkes disease (infant) | Yes | Yes | No | No | No | No | | Bariatric patient annual screen | Yes | Yes | No | Yes | Yes | No |

The AASLD 2023 guidance states: "Measurement of serum ceruloplasmin is the most practical initial screening test for Wilson disease, but it must be interpreted in combination with serum copper and 24-hour urine copper to avoid misclassification." That framing applies equally to deficiency states: no single test is sufficient.